Polish - B&B Pharmaceuticals (www.bbpharm.net), incorporated in 1997 and located in Aurora (Colorado), supplies controlled substances and pharmaceutical raw materials for pharmaceutical compounding to pharmacists in the United States. In 2012, B&B Pharmaceuticals' turnover is expected to be approximately US$ 6 million, with an EBITDA margin above the average for the Fagron Group. Fagron paid a multiple of 5.5 times EBITDA for this acquisition. B&B Pharmaceuticals will be consolidated as of 1 December 2012.
The range of B&B Pharmaceuticals' products fully complements Fagron's existing activities in the United States. By combining the activities of B&B Pharmaceuticals and Fagron, Fagron will be able to achieve clear benefits, not only in the areas of purchasing, analysis and production, but particularly in the areas of innovation and product assortment. From its offices in Aurora, St. Paul and Scottsdale, Fagron will be even better positioned to provide pharmacists in the United States with innovative concepts and products for pharmaceutical compounding.
Ger van Jeveren, founder and CEO of Fagron: 'We are delighted to welcome B&B Pharmaceuticals to the Fagron Group. This acquisition is a perfect match for our strategy of further extending Fagron's already strong market position in the United States.'
Jason Dassinger, former owner of B&B Pharmaceuticals: 'I am convinced that B&B Pharmaceuticals is an excellent match for Fagron. As a global market leader, Fagron is at the forefront of everything that has to do with pharmaceutical compounding. Our clients will benefit from the innovative and extensive range of products and concepts for pharmaceutical compounding offered by the Fagron Group. I'm greatly looking forward to making a contribution to the further growth of both B&B Pharmaceuticals and the Fagron Group after the acquisition.'.
Fagron wants to further strengthen its market leadership in the rapidly growing market for pharmaceutical compounding through an active buy-and-build strategy and robust organic growth. In 2013, the emphasis will be on acquisitions in Europe, as well as in North and South America.